Computational Modeling for Antiarrhythmic Drugs for Atrial Fibrillation According to Genotype

Catheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation

Background—The mainstay of treatment for atrial fibrillation (AF) remains pharmacological; however, catheter ablation has increasingly been used over the last decade. The relative merits of each strategy have not been extensively studied. Methods and Results—We conducted a randomized multicenter comparison of these 2 treatment strategies in patients with paroxysmal AF resistant to at least 1 an...

Can polymorphisms predict response to antiarrhythmic drugs in atrial fibrillation?

Ready or not, routine use of genetic information is imminent in everyday cardiology practice. This impending reality stems partly from the declining cost of whole-genome sequencing that is now approaching the $1,000 barrier. Clinicians undoubtedly could use such insight in managing atrial fibrillation (AF), an extremely common and costly condition. However, analyzing and applying the vast amoun...

Atrial Fibrillation Antiarrhythmic Drug Therapy for Atrial Fibrillation

Antiarrhythmic medications have been available for nearly 100 years and remain a mainstay in the management of atrial fibrillation (AF). Goals of therapy with the use of these drugs include a reduction in the frequency and duration of episodes of arrhythmia as well an emerging goal of reducing mortality and hospitalizations associated with AF. The use of these drugs has been limited by both pro...

New antiarrhythmic agents for atrial fibrillation.

22.12 (2002). 66. Beatch GN, Shinagawa K, Johnson BD et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. S. World. Congr. Pharmacol. 24, Abstract 21.11 (2002). 67. Cardiome drug effective for heart patients. Cardiome Pharma Corp. Press Release

Antiarrhythmic drugs in the management of atrial fibrillation.